Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and lowers the price target from $17 to $16.

Wells Fargo analyst Derek Archila maintains Zymeworks (NASDAQ:ZYME) with a Overweight and lowers the price target from $14 t...

Zymeworks (NYSE:ZYME) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.29) by ...

Zymeworks Inc. (NASDAQ:ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional bi...

Wells Fargo analyst Derek Archila maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $12 t...

HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Neutral and raises the price target fr...

Zymeworks (NASDAQ:ZYME) reported quarterly Adj losses of $(0.16) per share which beat the analyst consensus estimate of $(0.43)...

Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $0.14 per share on revenue o...

Five abstracts accepted for poster presentation highlight company's differentiated antibody-drug conjugate and multispecifi...